Catechol-O-methyltransferase (COMT), an enzyme that metabolizes catecholamines, has recently been implicated in the modulation of pain. Our group demonstrated that human genetic variants of COMT are predictive for the development of Temporomandibular Joint Disorder (TMJD) and are associated with heightened experimental pain sensitivity [Diatchenko, L, Slade, GD, Nackley, AG, Bhalang, K, Sigurdsson, A, Belfer, I, et al., Genetic basis for individual variations in pain perception and the development of a chronic pain condition, Hum Mol Genet 2005;14: 135-43.]. Variants associated with heightened pain sensitivity produce lower COMT activity. Here we report the mechanisms underlying COMT-dependent pain sensitivity. To characterize the means whereby elevated catecholamine levels, resulting from reduced COMT activity, modulate heightened pain sensitivity, we administered a COMT inhibitor to rats and measured behavioral responsiveness to mechanical and thermal stimuli. We show that depressed COMT activity results in enhanced mechanical and thermal pain sensitivity. This phenomenon is completely blocked by the nonselective b-adrenergic antagonist propranolol or by the combined administration of selective b 2 -and b 3 -adrenergic antagonists, while administration of b 1 -adrenergic, a-adrenergic, or dopaminergic receptor antagonists fail to alter COMT-dependent pain sensitivity. These data provide the first direct evidence that low COMT activity leads to increased pain sensitivity via a b 2/3 -adrenergic mechanism. These findings are of considerable clinical importance, suggesting that pain conditions resulting from low COMT activity and/or elevated catecholamine levels can be treated with pharmacological agents that block both b 2 -and b 3 -adrenergic receptors. Ó
Introduction
Catecholamines and enzymatic pathways that regulate the bioavailability of catecholamines influence persistent pain. Adrenergic systems contribute to the pathogenesis of rheumatoid arthritis in animals, as denervation of sympathetic noradrenergic fibers (Levine et al., 1986a ) and depletion of peripheral epinephrine (Coderre et al., 1990 ) attenuate arthritic responses. Additionally, chronic administration of b-adrenergic receptor (bAR) agonists produces a painful arthritis-like syndrome (Vyden et al., 1971) . These findings are consistent with clinical observations that sympathetic blockade or administration of the bAR antagonist propranolol reduces the severity of arthritis and joint responses to injury (Baerwald et al., 1997; Kaplan et al., 1980; Levine et al., 1986b) . 
